Summary: Fanconi's anemia (FA) is a genetic autosomal recessive disorder, characterized by progressive bone marrow failure, congenital abnormalities, growth retardation, and predisposition to leukemia and solid tumors. The purpose of this study was to compare the chronological age (CA), bone age (BA), and dental age (DA) of FA patients and to determine whether the therapy received influenced the BA or DA. Thirty FA patients were evaluated and divided into three groups according to the therapy received. Hand and wrist radiographs for BA estimation and panoramic radiographs for DA estimation were taken. Statistical analysis demonstrated that mean values for CA, BA, and DA were 8.91 years old, 7.90 years old, and 7.75 years old, respectively, indicating low mean values for BA and DA in comparison with CA (P<0.01). The therapy given to the patient did not influence the BA or DA. BA and DA are delayed and are not influenced by the therapy given.
F
anconi's anemia (FA) is an autosomal recessive disorder characterized by progressive bone marrow failure, congenital malformations, growth retardation, and predisposition to leukemia and solid tumors. 1 There are 11 genetic subtypes, named by complementation groups FA-A, B, C, D (D1 and D2), E, F, G, I, J, and L. 2 Growth delay in FA is associated with deficiency of growth hormone, observed in 81% of the patients. [3] [4] [5] Short stature is one of the most frequent clinical features of FA. 6 Morisaki et al 7 described the case of a child that showed delay of bone and dental ages.
FA diagnosis exploits the sensitivity of FA cells to alkylating agents, via cytogenetic analysis, imaging tests, blood cell analysis, and prenatal and preimplantational diagnosis. Hormonal treatment includes androgenic agents, glucocorticoids in association with androgens, hematopoietic growth factors, and transfusions; surgical care must be considered in some skeletal malformations. 5, 8 The natural history of the disease is bone marrow failure, leukemia, solid tumors, and death. The treatment of choice for FA is bone marrow transplantation, the only therapy that provides the potential for hematological cure, as well as umbilical cord stem cell transplantation. 9 Recently, gene therapy studies have been developed. 1, 5, 10 In addition, life expectancy has improved for FA patients, some of whom have survived into the second and third decade of life. 8 In light of the growth abnormalities found in FA, an investigation of chronological age (CA), bone age (BA), and dental age (DA) is necessary; no such studies have been performed previously.
MATERIALS AND METHODS

Sample
Thirty patients with FA were evaluated: 15 males and 15 females, aged 2 to 18 years, with an average age of 10 years. The sample was divided into three groups according to the therapy received. Group 1 included patients who were not taking any medicine, group 2 included patients taking oral androgen (oximetholone), and group 3 included patients taking oral androgen and also receiving blood transfusions. None of these patients were taking growth hormone.
Radiographic Examination
Hand and wrist radiographs (0.12 sec, 60 KV, 10-16 mA) were obtained to estimate bone age, and panoramic radiographs (13.2 sec, 60 KV, 10-16 mA) were obtained to estimate dental age.
Evaluation of Bone and Dental Ages
Hand and wrist radiographs were analyzed by two specialists in oral radiology, and panoramic radiographs were analyzed by a specialist in oral radiology and by a specialist in forensic dentistry. Both radiographs were interpreted with use of a viewing box. The specialists were previously standardized and double-blinded.
Criteria for Evaluation of Bone and Dental Ages
The Greulich and Pyle Atlas 11 was used to estimate the BA. In this evaluation the examiners were allowed to know the patient's sex but not the CA.
A table of the chronological mineralization of permanent teeth among Brazilians by Nicodemo et al 12 was followed to estimate the DA. Knowledge of the CA and BA of the patients was not allowed.
RESULTS
After estimation of BA and DA, the results were submitted to statistical analysis.
Dalhberg's test was used to analyze the examiners' evaluations, showing a 100% reliability coefficient for BA and 99.99% for DA.
The descriptive statistics of the variables CA, BA, and DA were calculated. The mean values for these variables were 8.91 years old, 7.90 years old, and 7.75 years old, respectively (Table 1) .
Statistical differences between the pairs of data CA and BA, CA and DA, and BA and DA were evaluated with Student's t test for paired samples. BA and DA showed mean values lower than CA (P<0.01; Table 2 ).
The ANOVA test was employed to verify whether there was any statistical difference in the mean delay between BA and CA versus DA and CA in the three analyzed therapy groups. Results did not show statistically significant differences in the mean delay of BA and DA among the three therapy groups (P<0.05; Table 3 ).
DISCUSSION
No similar study was found in a literature review. BA delay was described in reports of cases and as one of the clinical manifestations of an FA patient, and DA delay was described for one other patient. Therefore, this study report is the first to describe the relation between CA, BA, and DA in FA patients, with a significant sample. It is expected that this research will provide information relevant to future studies of the disease.
The delay of BA observed in FA patients in this study is in agreement with reports of cases of FA in which bone growth retardation was described. 9, [13] [14] [15] [16] Bone growth retardation was described in the literature as one of the most common clinical manifestations of FA. 1, 5, 6, 8 Our findings are in agreement with that assessment.
Growth retardation in FA is associated with growth hormone deficiency. 3 Wajnrajcn and Gertner 4 evaluated growth and hormonal conditions in 54 patients with FA and observed bone growth retardation and growth hormone deficiency in 44 (81%). These findings are in agreement with ours for BA. In this study growth hormone was not evaluated, and none of the patients had taken this hormone as treatment.
A delay of BA and DA was verified in patients with FA, as observed in a report by Morisaki et al 7 of a child with FA, thus confirming this as a clinical characteristic of FA. BA and DA are delayed and do not correspond with CA; they also are not associated with treatment but rather to FA, and they can be considered a relevant condition of the disease.
This study allowed us to estimate BA and DA with the knowledge of CA, even without radiographs, thereby avoiding exposure of patients to radiation.
